WallStSmart

Caring Brands, Inc. Common Stock (CABR)vsZoetis Inc (ZTS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Zoetis Inc generates 347086572% more annual revenue ($9.53B vs $2,746). ZTS leads profitability with a 28.0% profit margin vs 0.0%. ZTS earns a higher WallStSmart Score of 66/100 (B-).

CABR

Avoid

15

out of 100

Grade: F

Growth: 2.7Profit: 2.5Value: 5.0Quality: 5.8
Piotroski: 5/9Altman Z: -5.82

ZTS

Strong Buy

66

out of 100

Grade: B-

Growth: 5.3Profit: 10.0Value: 6.0Quality: 7.0
Piotroski: 4/9Altman Z: 3.14
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for CABR.

ZTSUndervalued (+11.5%)

Margin of Safety

+11.5%

Fair Value

$145.45

Current Price

$75.89

$69.56 discount

UndervaluedFair: $145.45Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CABR0 strengths · Avg: 0/10

No standout strengths identified

ZTS5 strengths · Avg: 9.4/10
Return on EquityProfitability
81.8%10/10

Every $100 of equity generates 82 in profit

Operating MarginProfitability
36.6%10/10

Strong operational efficiency at 36.6%

Altman Z-ScoreHealth
3.1410/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
28.0%9/10

Keeps 28 of every $100 in revenue as profit

P/E RatioValuation
13.0x8/10

Attractively priced relative to earnings

Areas to Watch

CABR4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$10.91M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-217.1%2/10

ROE of -217.1% — below average capital efficiency

ZTS4 concerns · Avg: 3.3/10
PEG RatioValuation
1.914/10

Expensive relative to growth rate

Price/BookValuation
9.7x4/10

Trading at 9.7x book value

Revenue GrowthGrowth
2.9%4/10

2.9% revenue growth

Debt/EquityHealth
2.861/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : CABR

CABR has a balanced fundamental profile.

Bull Case : ZTS

The strongest argument for ZTS centers on Return on Equity, Operating Margin, Altman Z-Score. Profitability is solid with margins at 28.0% and operating margin at 36.6%.

Bear Case : CABR

The primary concerns for CABR are EPS Growth, Market Cap, Profit Margin.

Bear Case : ZTS

The primary concerns for ZTS are PEG Ratio, Price/Book, Revenue Growth. Debt-to-equity of 2.86 is elevated, increasing financial risk.

Key Dynamics to Monitor

ZTS is growing revenue faster at 2.9% — sustainability is the question.

ZTS generates stronger free cash flow (291M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

ZTS scores higher overall (66/100 vs 15/100), backed by strong 28.0% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Caring Brands, Inc. Common Stock

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Caring Brands, Inc., a wellness consumer products company, provides over-the-counter and cosmetic consumer products. The company is headquartered in Fort Pierce, Florida.

Zoetis Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Zoetis Inc. is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock.

Visit Website →

Want to dig deeper into these stocks?